Search

Your search keyword '"Palandri F."' showing total 266 results
Start Over Author "Palandri F." Publication Year Range Last 10 years
266 results on '"Palandri F."'

3. Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series.

Author

Palandri, F., Branzanti, F., Benevolo, G., Beggiato, E., Morsia, E., Dedola, A., Loffredo, M., Fontana, G., Palumbo, G. A., Breccia, M., and Tiribelli, M.

Subjects
*BROMODOMAIN-containing proteins, *LEUCOCYTES, *ADVERSE health care events, *URINARY tract infections, *ACUTE kidney failure, *MYELOFIBROSIS
Abstract

The article discusses the use of ruxolitinib after fedratinib failure in patients with myelofibrosis. It presents a case series of 14 patients who received ruxolitinib after fedratinib therapy, detailing their clinical outcomes and responses. The study highlights the potential clinical benefit of second-line ruxolitinib, achieving spleen and symptoms response in a subset of patients. The findings suggest that sequential use of ruxolitinib after fedratinib may be beneficial for selected patients, with no observed excess toxicity in the second-line setting. [Extracted from the article]

Published
2024
Full Text
View/download PDF

5. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study

Author

Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., Palandri F., Elli, E, Di Veroli, A, Bartoletti, D, Iurlo, A, Carmosino, I, Benevolo, G, Abruzzese, E, Bonifacio, M, Bergamaschi, M, Polverelli, N, Caramella, M, Cilloni, D, Tiribelli, M, Pugliese, N, Caocci, G, Crisa, E, Porrini, R, Markovic, U, Renso, R, Auteri, G, Cattaneo, D, Trawinska, M, Scaffidi, L, Biale, L, Bucelli, C, Breccia, M, Gambacorti Passerini, C, Palumbo, G, Latagliata, R, Palandri, F, Elli E. M., Di Veroli A., Bartoletti D., Iurlo A., Carmosino I., Benevolo G., Abruzzese E., Bonifacio M., Bergamaschi M., Polverelli N., Caramella M., Cilloni D., Tiribelli M., Pugliese N., Caocci G., Crisa E., Porrini R., Markovic U., Renso R., Auteri G., Cattaneo D., Trawinska M. M., Scaffidi L., Biale L., Bucelli C., Breccia M., Gambacorti Passerini C., Palumbo G. A., Latagliata R., and Palandri F.

Abstract

Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX-IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX for IOL to assess: safety, efficacy in term of iron chelation response (ICR) and erythroid response (ER), and impact on overall survival of the combination therapy. The RUX–DFX therapy was administered for a median time of 12.4 months (interquartile range 3.1–71.2). During treatment, 36 (52.2%) and 34 (49.3%) patients required RUX and DFX dose reductions, while eight (11.6%) and nine (13.1%) patients discontinued due to RUX- or DFX-related adverse events; no unexpected toxicity was reported. ICR and ER were achieved by 33 (47.8%) and 32 patients (46.4%) respectively. Thirteen (18.9%) patients became transfusion-independent. Median time to ICR and ER was 6.2 and 2 months respectively. Patients achieving an ER were more likely to obtain an ICR also (p = 0.04). In multivariable analysis, the absence of leukocytosis at baseline (p = 0.02) and achievement of an ICR at any time (p = 0.02) predicted improved survival. In many MF patients, the RUX–DFX combination provided ICR and ER responses that correlated with improved outcome in the absence of unexpected toxicities. This strategy deserves further clinical investigation.

Published
2022

6. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F, Giorgino, T, Mora, B, Guglielmelli, P, Rumi, E, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R T, Benevolo, G, Albano, F, Caramazza, D, Merli, M, Pietra, D, Casalone, R, Rotunno, G, Barbui, T, Cazzola, M, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

7. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, M.T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, S.F., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, A.M., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, E.M., Luppi, M., Marasca, R., Pogliani, E.M., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, M.C., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, A.M., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., D'Emilio, A., Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., and Rosti, G.

Published
2015
Full Text
View/download PDF

8. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Author

Passamonti, F, Mora, B, Giorgino, T, Guglielmelli, P, Cazzola, M, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, J J, Cervantes, F, Devos, T, Palandri, F, De Stefano, V, Ruggeri, M, Silver, R, Benevolo, G, Albano, F, Caramazza, D, Rumi, E, Merli, M, Pietra, D, Casalone, R, Barbui, T, Pieri, L, and Vannucchi, A M

Published
2017
Full Text
View/download PDF

9. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Author

Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, Palandri F, Specchia G, Liberati AM, D’Adda M, Gaidano G, Fjerza R, Achenbach H, Smith J, Wilde P, and Vannucchi AM

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Nicola Cascavilla,1 Valerio De Stefano,2 Fabrizio Pane,3 Alessandro Pancrazzi,4 Alessandra Iurlo,5 Marco Gobbi,6 Francesca Palandri,7 Giorgina Specchia,8 A Marina Liberati,9 Mariella D’Adda,10 Gianluca Gaidano,11 Rajmonda Fjerza,4 Heinrich Achenbach,12 Jonathan Smith,13 Paul Wilde,13 Alessandro M Vannucchi41Division of Hematology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy; 2Institute of Hematology, Catholic University, Rome, Italy; 3Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 4Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 5Oncohematology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy; 6IRCCS AOU San Martino, Genova, Italy; 7Department of Specialistic, Diagnostic and Experimental Medicine, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 8Unit of Hematology with Transplantation, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy; 9Ospedale Santa Maria, Terni, Italy; 10Division of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy; 11Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 12Research and Development, Shire GmbH, Eysins, Switzerland; 13Shire Pharmaceutical Development Ltd, Basingstoke, United KingdomAbstract: A JAK2(V617F) mutation is found in approximately 55% of patients with essential thrombocythemia (ET), and represents a key World Health Organization diagnostic criterion. This hypothesis-generating study (NCT01352585) explored the impact of JAK2(V617F) mutation status on treatment response to anagrelide in patients with ET who were intolerant/refractory to their current cytoreductive therapy. The primary objective was to compare the proportion of JAK2-positive versus JAK2-negative patients who achieved at least a partial platelet response (≤600×109/L) after anagrelide therapy. Of the 47 patients enrolled, 46 were included in the full analysis set (JAK2-positive, n=22; JAK2-negative, n=24). At 12 months, 35 patients (n=14 and n=21, respectively) had a suitable platelet sample; of these, 74.3% (n=26) achieved at least a partial response. The response rate was higher in JAK2-positive (85.7%, n=12) versus JAK2-negative patients (66.7%, n=14) (odds ratio [OR] 3.00; 95% confidence interval [CI] 0.44, 33.97). By using the last observation carried forward approach in the sensitivity analysis, which considered the imbalance in patients with suitable samples between groups, the overall response rate was 71.7% (n=33/46), with 77.3% (n=17/22) of JAK2-positive and 66.7% (n=16/24) of JAK2-negative patients achieving at least a partial response (OR 1.70; 95% CI 0.39, 8.02). There was no significant change in median allele burden over 12 months in the 12 patients who achieved a response. In conclusion, the overall platelet response rate was high in both JAK2-positive and JAK2-negative patients; however, a larger study would be required to confirm the differences observed according to JAK2(V617F) mutation status.Keywords: essential thrombocythemia, mutation, JAK2, anagrelide, treatment response, allele burden

Published
2015

10. P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME

Author

Palandri, F., primary, Bartoletti, D., additional, Breccia, M., additional, Auteri, G., additional, Elli, E. M., additional, Trawinska, M. M., additional, Polverelli, N., additional, Tiribelli, M., additional, Benevolo, G., additional, Iurlo, A., additional, Tieghi, A., additional, Heidel, F. H., additional, Caocci, G., additional, Beggiato, E., additional, Binotto, G., additional, Cavazzini, F., additional, Miglino, M., additional, Bosi, C., additional, Crugnola, M., additional, Bocchia, M., additional, Martino, B., additional, Pugliese, N., additional, Romagnoli, A. D., additional, Mazzoni, C., additional, Scaffidi, L., additional, Isidori, A., additional, Cattaneo, D., additional, Krampera, M., additional, Pane, F., additional, Cilloni, D., additional, Semenzato, G., additional, Lemoli, R. M., additional, Cuneo, A., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Bonifacio, M., additional, and Palumbo, G. A., additional

Published
2022
Full Text
View/download PDF

11. S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY

Author

Mascarenhas, J., primary, Kremyanskaya, M., additional, Patriarca, A., additional, Harrison, C., additional, Bose, P., additional, Rampal, R. K., additional, Palandri, F, additional, Devos, T., additional, Passamonti, F., additional, Hobbs, G., additional, Talpaz, M., additional, Vannucchi, A., additional, Kiladjian, J.-J., additional, Verstovsek, S., additional, Hoffman, R., additional, Salama, M. E., additional, Chen, D., additional, Taverna, P., additional, Chang, A., additional, Colak, G., additional, Klein, S., additional, and Gupta, V., additional

Published
2022
Full Text
View/download PDF

12. P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Author

Mora, B., primary, Guglielmelli, P., additional, Kuykendall, A., additional, Maffioli, M., additional, Rotunno, G., additional, Komrokji, R. S., additional, Palandri, F., additional, Kiladjian, J.-J., additional, Iurlo, A., additional, Auteri, G., additional, Cattaneo, D., additional, De Stefano, V., additional, Salmoiraghi, S., additional, Devos, T., additional, Cervantes, F., additional, Merli, M., additional, Campagna, A., additional, Benevolo, G., additional, Brociner, M., additional, Albano, F., additional, Gotlib, J., additional, Caramella, M., additional, Ruggeri, M., additional, Ross, D. M., additional, Orsini, F., additional, Pessina, C., additional, Colugnat, I., additional, Pallotti, F., additional, Barbui, T., additional, Bertù, L., additional, Della Porta, M. G., additional, Vannucchi, A. M., additional, and Passamonti, F., additional

Published
2022
Full Text
View/download PDF

13. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

Author

Barbui, T., primary, Carobbio, A., additional, Masciulli, A., additional, Iurlo, A., additional, Sobas, M. A., additional, Elli, E. M., additional, Rumi, E., additional, De Stefano, V., additional, Lunghi, F., additional, Marchetti, M., additional, Daffini, R., additional, Gasior Kabat, M., additional, Cuevas, B., additional, Fox, M. L., additional, Andrade Campos, M. M., additional, Palandri, F., additional, Guglielmelli, P., additional, Benevolo, G., additional, Harrison, C., additional, Foncillas, M. A., additional, Bonifacio, M., additional, Alvarez-Larran, A., additional, Kiladjian, J.-J., additional, Bolanos Calderon, E., additional, Patriarca, A., additional, Quiroz Cervantes, K. S., additional, Griesshammer, M., additional, Garcia-Gutierrez, V., additional, Marin Sanchez, A., additional, Magro Mazo, E., additional, Ruggeri, M., additional, Hernandez-Boluda, J. C., additional, Osorio, S., additional, Carreno-Tarragona, G., additional, Sagues Serrano, M., additional, Kusec, R., additional, Navas Elorza, B., additional, Angona, A., additional, Xicoy Cirici, B., additional, Lopez Abadia, E., additional, Koschmieder, S., additional, Cichocka, E., additional, Kulikowska de Nałęcz, A., additional, Bellini, M., additional, Cattaneo, D., additional, Bucelli, C., additional, Cavalca, F., additional, Borsani, O., additional, Betti, S., additional, Curto-Garcia, N., additional, Carbonell, S., additional, Benajiba, L., additional, Rambaldi, A., additional, and Vannucchi, A. M., additional

Published
2022
Full Text
View/download PDF

14. P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS

Author

Harrison, C., primary, Rampal, R. K., additional, Gupta, V., additional, Verstovsek, S., additional, Talpaz, M., additional, Kiladjian, J.-J., additional, Mesa, R., additional, Kuykendall, A., additional, Vannucchi, A., additional, Palandri, F., additional, Grosicki, S., additional, Devos, T., additional, Jourdan, E., additional, Wondergem, M. J., additional, Al-Ali, H. K., additional, Buxhofer-Ausch, V., additional, Alvarez-Larrán, A., additional, Akhani, S., additional, Muñoz-Carerras, R., additional, Sheykin, Y., additional, Colak, G., additional, Harris, M., additional, and Mascarenhas, J., additional

Published
2022
Full Text
View/download PDF

15. P1051: A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

Author

Gill, H., primary, Yacoub, A., additional, Pettit, K., additional, Bradley, T., additional, Gerds, A., additional, Tatarczuch, M., additional, Shortt, J., additional, Curtin, N., additional, Rossetti, J., additional, Burbury, K., additional, Mead, A., additional, Göthert, J., additional, Koschmieder, S., additional, Jones, A., additional, Peppe, J., additional, Dias, J., additional, Natsoulis, G., additional, McClure, T., additional, Kleppe, M., additional, Hong, W.-J., additional, Stevenson, W., additional, Ewing, J., additional, Chacko, J., additional, Rumi, E., additional, Halpern, A., additional, Palandri, F., additional, Vianelli, N., additional, Passamonti, F., additional, Mesa, R., additional, Marchetti, M., additional, Harrison, C., additional, Vannucchi, A., additional, Watts, J., additional, Ross, D., additional, Talpaz, M., additional, and Rienhoff, H., additional

Published
2022
Full Text
View/download PDF

16. P1011: PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB

Author

Palandri, F., primary, Bartoletti, D., additional, Elli, E. M., additional, Auteri, G., additional, Bonifacio, M., additional, Benevolo, G., additional, Heidel, F., additional, Trawinska, M. M., additional, Rossi, E., additional, Bosi, C., additional, Tieghi, A., additional, Tiribelli, M., additional, Iurlo, A., additional, Polverelli, N., additional, Caocci, G., additional, Binotto, G., additional, Cavazzini, F., additional, Beggiato, E., additional, Cilloni, D., additional, Tatarelli, C., additional, Mendicino, F., additional, Miglino, M., additional, Bocchia, M., additional, Crugnola, M., additional, Mazzoni, C., additional, Romagnoli, A. D., additional, Rindone, G., additional, Ceglie, S., additional, D’Addio, A., additional, Santoni, E., additional, Cattaneo, D., additional, Lemoli, R. M., additional, Krampera, M., additional, Cuneo, A., additional, Semenzato, G., additional, Latagliata, R., additional, Abruzzese, E., additional, Vianelli, N., additional, Cavo, M., additional, Andriani, A., additional, De Stefano, V., additional, Palumbo, G., additional, and Breccia, M., additional

Published
2022
Full Text
View/download PDF

17. P1033: A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

Author

Palandri, F., primary, Ross, D. M., additional, Cochrane, T., additional, Tate, C., additional, Lane, S. W., additional, Larsen, S. R., additional, Gerds, A. T., additional, Halpern, A. B., additional, Shortt, J., additional, Rossetti, J. M., additional, Pettit, K. M., additional, Liang, J., additional, Mead, A., additional, Marchetti, M., additional, Vannucchi, A., additional, Wilson, A., additional, Göthert, J. R., additional, Hanna, M., additional, Jones, A., additional, Peppe, J., additional, Natsoulis, G., additional, McClure, T., additional, Hong, W.-J., additional, Stevenson, W. S., additional, Harrison, C. N., additional, Talpaz, M., additional, Vianelli, N., additional, and Rienhoff, H. Y., additional

Published
2022
Full Text
View/download PDF

18. P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS

Author

Vannucchi, A., primary, Pemmaraju, N., additional, Scott, B., additional, Savona, M., additional, Oh, S., additional, Palandri, F., additional, Al-Ali, H. K., additional, Sobas, M., additional, McMullin, M. F., additional, Gupta, V., additional, Yacoub, A., additional, Mesa, R., additional, Buckley, S., additional, Roman-Torres, K., additional, Verstovsek, S., additional, and Harrison, C., additional

Published
2022
Full Text
View/download PDF

20. Determinants of early triage for hospitalization in MPN patients with COVID-19

Author

Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas M, Elli E, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox M, Andrade-Campos M, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas M, Bonifacio M, Alvarez-Larran A, Kiladjian J, Calderon E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Mazo E, Carli G, Hernandez-Boluda J, Osorio S, Carreno-Tarragona G, Serrano M, Kusec R, Elorza B, Angona A, Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nalecz A, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, and Vannucchi A

Published
2022

22. Differences among young adults, adults and elderly chronic myeloid leukemia patients

Author

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., Abruzzese, E., Rossi, G., Iurlo, A., Martino, B., Pregno, P., Stagno, F., Cuneo, A., Bonifacio, M., Gobbi, M., Russo, D., Gozzini, A., Tiribelli, M., de Vivo, A., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Salvi, F., Pini, M., Leoni, P., Rupoli, S., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Albano, F., Russo Rossi, A., Rambaldi, A., Intermesoli, T., Palandri, F., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Bochicchio, MT., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Malagola, M., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., Storti, S., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Impera, S., Molica, S., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cavazzini, F., Bosi, A., Santini, V., Capalbo, SF., Spinosa, G., Pierri, I., Bergamaschi, M., Carella, AM., Bacigalupo, A., De Blasio, A., Ciccone, F., Di Renzo, N., Musolino, C., Russo, S., Cortelezzi, A., Morra, E., Pungolino, EM., Luppi, M., Marasca, R., Pogliani, EM., Gambacorti-Passerini, C., Luciano, L., Ferrara, F., Annunziata, M., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Aversa, F., Crugnola, M., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidori, A., Fioritoni, G., Di Lorenzo, R., Vallisa, D., Trabacchi, E., Petrini, M., Galimberti, S., Pizzuti, M., Zaccaria, A., Salvucci, M., Ronco, F., Ielo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Musto, P., De Stefano, V., Sica, S., Latagliata, R., De Fabritiis, P., Trawiska, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Petti, MC., Pisani, F., Tafuri, A., Montefusco, E., Iuliano, F., Dore, F., Pardini, S., Bocchia, M., Defina, M., Liberati, AM., Luzzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Gherlinzoni, F., Calistri, E., Fanin, R., Pizzolo, G., Meneghini, V., Rodighiero, F., and DʼEmilio, A.

Published
2015
Full Text
View/download PDF

23. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

Author

Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J, Griesshammer M, Mesa R, Ianotto J, Palandri F, Hernandez-Boluda J, Birgegard G, Nangalia J, Koschmieder S, Rumi E, and Barbui T

Abstract

Recommendations regarding management of essential thrombocythaemia rely on studi e s done before the discovery of the CALR mutation. On May 20, 2020, the Europ e a n LeukemiaNet annual meeting was held with the goal to identify unmet clin i c a l needs in myeloproliferative neoplasms. Because patients with a CALR mutation have specific clinica l characteristics, treatment of CALR-mutated essential thrombocythaemia was considered an unmet clinical need by the Europ e a n LeukemiaNet. The elaboration of a consensus document with recommendations according to current evidence was proposed as a solution for resolving uncertainties in the treatment of CALR-mutated essential thrombocythaemia. A steering committee comprising f o u r Europ e a n LeukemiaNet members was t h e n formed and a panel of ten experts in the field was recruited. T h e experts proposed 51 potential unmet clinical needs in the management of CALR-mutated essential thrombocythaemia and were as k e d to score the relevance of each topic. Those topics that obtained the highest scores as relevant unmet clinical needs were identified, including antiplat e l e t therapy in patients at low risk, definition of extreme thrombocytosis and its management in patients at low risk, indications of cytoreduction and tar g e t s of therapy, first-line treatment of choice in young patients (1500 x 109 platelets per L) with pegylated interfe r o n alfa being the preferred option for younger patients; both hydroxycarbamide and anagrelide might be given to patients ineligible for pegylated interferon alfa; and treatment algorithms for patients with high-risk pregnancies should not be changed according to genotype. The European LeukemiaNet proposes to use these recommendations in the routine management of patients wit h CALR-mutated essential thrombocythaemia, and designing new clinica l studies in this field might be useful.

Published
2021

24. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

Author

De Stefano, V., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, E., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., McMullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., De Stefano V. (ORCID:0000-0002-5178-5827), Rossi E. (ORCID:0000-0002-7572-9379), De Stefano, V., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, E., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., McMullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., De Stefano V. (ORCID:0000-0002-5178-5827), and Rossi E. (ORCID:0000-0002-7572-9379)

Abstract

Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n 5 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P 5 .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P 5 .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P 5 .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma.

Published
2020

25. Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years

Author

Palandri, F., Santoro, C., Carpenedo, M., Cantoni, S., Barcellini, W., Carli, G., Carrai, V., Rossi, E., Rivolti, E., Lucchesi, A., Rotondo, F., Baldacci, E., Auteri, G., Sutto, E., Di Pietro, C., Catani, L., Bartoletti, D., De Stefano, V., Ruggeri, M., Mazzucconi, M. G., Cavo, M., Rodeghiero, F., Vianelli, N., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Palandri, F., Santoro, C., Carpenedo, M., Cantoni, S., Barcellini, W., Carli, G., Carrai, V., Rossi, E., Rivolti, E., Lucchesi, A., Rotondo, F., Baldacci, E., Auteri, G., Sutto, E., Di Pietro, C., Catani, L., Bartoletti, D., De Stefano, V., Ruggeri, M., Mazzucconi, M. G., Cavo, M., Rodeghiero, F., Vianelli, N., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Introduction: Primary Immune thrombocytopenia (ITP) in the elderly is a major clinical challenge which is increasingly frequent due to global ageing population. Materials and methods: To describe baseline ITP features, management, and outcome, a centralized electronic database was established, including data of 451 patients aged ≥60 years that were treated from 2000 onwards and were observed for ≥1 year (total observation of 2704 patient-years). Results: At ITP diagnosis, median age was 71.1 years (age ≥ 75: 42.8%); 237 (53.9%) patients presented with haemorrhages (grade ≥ 3: 7.5%). First-line therapy included prednisone (82.9%), dexamethasone (14.6%), thrombopoietin-receptor agonists (TRAs, 1.3%), and oral immunosuppressive agents (1.1%). Prednisone starting dose ≥1 mg/kg/d (p = .01) and dexamethasone 40 mg/d (p < .001) were mainly reserved to patients aged 60–74, who were more treated with rituximab (RTX, p = .02) and splenectomy (p = .03) second-line. Overall response rates to first and second-line therapies were 83.8% and 84.5%, respectively, regardless of age and treatment type/dose. A total of 178 haemorrhages in 101 patients (grade ≥ 3: n. 52, 29.2%; intracranial in 6 patients), 49 thromboses in 43 patients (grade ≥ 3: n. 26, 53.1%) and 115 infections in 94 patients (grade ≥ 3: n. 23, 20%) were observed during follow-up. Incidence rates of complications per 100 patient-years were: 4.5 (haemorrhages, grade ≥ 3: 1.7), 1.7 (thromboses, grade ≥ 3: 0.9), and 3.9 (infections, grade ≥ 3: 0.7). TRAs use were associated with reduced risk of bleeding and infections, while cardiovascular risk factors (particularly, diabetes) significantly predicted thromboses and infections. Conclusions: Age-adapted treatment strategies are required in elderly and very elderly patients.

Published
2020

26. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., Rambaldi, A., De Stefano V. (ORCID:0000-0002-5178-5827), Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., Rambaldi, A., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2020

27. Second cancers in MPN: Survival analysis from an international study

Author

Marchetti, M., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, Elena, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Pane, F., De Stefano, Valerio, Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Marchetti, M., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Rossi, Elena, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Rapezzi, D., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Pane, F., De Stefano, Valerio, Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Rambaldi, A., Barbui, T., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

One out of ten patients with Philadelphia-negative myeloproliferative neoplasms (MPN) develop a second cancer (SC): in such patients we aimed at assessing the survival impact of SC itself and of MPN-specific therapies. Data were therefore extracted from an international nested case-control study, recruiting 798 patients with SC diagnosed concurrently or after the MPN. Overall, 2995 person-years (PYs) were accumulated and mortality rate (MR) since SC diagnosis was 5.9 (5.1-6.9) deaths for every 100 PYs. A “poor prognosis” SC (stomach, esophagus, liver, pancreas, lung, ovary, head-and-neck or nervous system, osteosarcomas, multiple myeloma, aggressive lymphoma, acute leukemia) was reported in 26.3% of the patients and was the cause of death in 65% of them (MR 11.0/100 PYs). In contrast, patients with a “non-poor prognosis” SC (NPPSC) incurred a MR of 4.6/100 PYs: 31% of the deaths were attributed to SC and 15% to MPN evolution. At multivariable analysis, death after SC diagnosis was independently predicted (HR and 95% CI) by patient age greater than 70 years (2.68; 1.88-3.81), the SC prognostic group (2.57; 1.86-3.55), SC relapse (1.53; 10.6-2.21), MPN evolution (2.72; 1.84-4.02), anemia at SC diagnosis (2.32; 1.49-3.59), exposure to hydroxyurea (1.89; 1.26-2.85) and to ruxolitinib (3.63; 1.97-6.71). Aspirin was protective for patients with a NPPSC (0.60; 0.38-0.95). In conclusion, SC is a relevant cause of death competing with MPN evolution. Prospective data are awaited to confirm the role of cytoreductive and anti-platelet drugs in modulating patient survival after the occurrence of a SC.

Published
2020

28. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Author

Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2020

30. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Author

Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Published
2019

31. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Author

Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., De Stefano, Valerio, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Finazzi, G., De Stefano V. (ORCID:0000-0002-5178-5827), Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., De Stefano, Valerio, Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A. M., Finazzi, G., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82–1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15–4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00–14.01), ruxolitinib (OR = 3.87, 95% CI 1.18–12.75), and for drug combination (OR = 3.47, 95% CI 1.55–7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.

Published
2019

32. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

Author

Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., Sordi, B., Albano, F., Breccia, M., De Stefano, Valerio, Finazzi, G., Iurlo, A., Martino, B., Palandri, F., Passamonti, F., Siragusa, S., Mannelli, L., Fantoni, D., Fazi, P., Amadori, S., Vignetti, M., Barbui, T., Vannucchi, A. M., De Stefano V. (ORCID:0000-0002-5178-5827), Loscocco, G. G., Mannelli, F., Guglielmelli, P., Paoli, C., Marone, I., Cucci, R., Coltro, G., Sordi, B., Albano, F., Breccia, M., De Stefano, Valerio, Finazzi, G., Iurlo, A., Martino, B., Palandri, F., Passamonti, F., Siragusa, S., Mannelli, L., Fantoni, D., Fazi, P., Amadori, S., Vignetti, M., Barbui, T., Vannucchi, A. M., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2019

33. Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

Author

Breccia, M., Luciano, L., Pugliese, N., Rossi, Elena, Tiribelli, M., Scalzulli, E., Bonifacio, M., Martino, B., Latagliata, R., Benevolo, G., Caocci, G., Binotto, G., Martinelli, V., Cavo, M., Pane, F., De Stefano, Valerio, Foa, R., Palandri, F., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Breccia, M., Luciano, L., Pugliese, N., Rossi, Elena, Tiribelli, M., Scalzulli, E., Bonifacio, M., Martino, B., Latagliata, R., Benevolo, G., Caocci, G., Binotto, G., Martinelli, V., Cavo, M., Pane, F., De Stefano, Valerio, Foa, R., Palandri, F., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p = 0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed.

Published
2019

34. Risk factors for secondary cancer in a case-control study on 1,881 patients with myeloproliferative neoplasms (ELN Study)

Author

Barbui, T., Ghirardi, A., Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Destefano, V., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Delaini, F., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Stephensom, C., Guglielmelli, P., Elli, E. M., Miroslava, P., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benelovo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Rcasens Flores, V., Marchetti, M., Griesshammer, M., Alvarez-Larran, A., Vannucchi, A., and Finazzi, G.

Published
2018

35. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., and Rambaldi, A.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Aspirin, business.industry, Hematology, Second primary cancer, Settore MED/15 - MALATTIE DEL SANGUE, Internal medicine, medicine, business, Myelopriferative neoplasms, medicine.drug
Published
2019

36. PS1458 RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

Author

Mora, B., primary, Guglielmelli, P., additional, Rumi, E., additional, Maffioli, M., additional, Barraco, D., additional, Rambaldi, A., additional, Caramella, M., additional, Komrokji, R., additional, Kiladjian, J.J., additional, Gotlib, J., additional, Iurlo, A., additional, Cervantes, F., additional, Devos, T., additional, Palandri, F., additional, De Stefano, V., additional, Ruggeri, M., additional, Silver, R.T., additional, Benevolo, G., additional, Albano, F., additional, Cavalloni, C., additional, Pietra, D., additional, Barbui, T., additional, Rotunno, G., additional, Bertù, L., additional, Cazzola, M., additional, Vannucchi, A.M., additional, and Passamonti, F., additional

Published
2019
Full Text
View/download PDF

37. PF674 OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

Author

Palandri, F., primary, Breccia, M., additional, Bonifacio, M., additional, Polverelli, N., additional, Elli, E.M., additional, Benevolo, G., additional, Tiribelli, M., additional, Abruzzese, E., additional, Iurlo, A., additional, Heidel, F., additional, Bergamaschi, M., additional, Tieghi, A., additional, Crugnola, M., additional, Cavazzini, F., additional, Binotto, G., additional, Isidori, A., additional, Sgherza, N., additional, Bosi, C., additional, Martino, B., additional, Latagliata, R., additional, Auteri, G., additional, Scaffidi, L., additional, Griguolo, D., additional, Trawinska, M., additional, Cattaneo, D., additional, Catani, L., additional, Krampera, M., additional, Vitolo, U., additional, Lemoli, R.M., additional, Cuneo, A., additional, Semenzato, G., additional, Foà, R., additional, Raimondo, F. Di, additional, Bartoletti, D., additional, Cavo, M., additional, Palumbo, G.A., additional, and Vianelli, N., additional

Published
2019
Full Text
View/download PDF

38. PF695 ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

Author

Lucchini, E., primary, Palandri, F., additional, Volpetti, S., additional, Vianelli, N., additional, Auteri, G., additional, Rossi, E., additional, Patriarca, A., additional, Carli, G., additional, Barcellini, W., additional, Rotondo, F., additional, Consoli, U., additional, Valeri, F., additional, Santoro, C., additional, Crea, E., additional, Vignetti, M., additional, Boggio, E., additional, Dianzani, U., additional, Giardini, I., additional, Carpenedo, M., additional, Rodeghiero, F., additional, Fanin, R., additional, and Zaja, F., additional

Published
2019
Full Text
View/download PDF

39. PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

Author

Barbui, T., primary, Ghirardi, A., additional, Masciulli, A., additional, Carobbio, A., additional, Palandri, F., additional, Vianelli, N., additional, De Stefano, V., additional, Betti, S., additional, Di Veroli, A., additional, Iurlo, A., additional, Cattaneo, D., additional, Delaini, F., additional, Bonifacio, M., additional, Scaffidi, L., additional, Patriarca, A., additional, Rumi, E., additional, Stephenson, C., additional, Guglielmelli, P., additional, Elli, E.M., additional, Miroslava, P., additional, Bertolotti, L., additional, Erez, D., additional, Gomez, M., additional, Wille, K., additional, Perez-Encinas, M., additional, Lunghi, F., additional, Angona, A., additional, Fox, M.L., additional, Beggiato, E., additional, Benevolo, G., additional, Carli, G., additional, Cacciola, R., additional, McMullin, M.F., additional, Tieghi, A., additional, Recasens, V., additional, Marchetti, M., additional, Griesshammer, M., additional, Alvarez-Larran, A., additional, Vannucchi, A., additional, and Finazzi, G., additional

Published
2019
Full Text
View/download PDF

40. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Author

Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

41. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

42. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

43. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Author

De Stefano, Valerio, Rocca, Bianca, Tosetto, A, Soldati, Denise, Petrucci, Giovanna, Beggiato, E, Bertozzi, I, Betti, Silvia, Carli, G, Carpenedo, M, Cattaneo, D, Cavalca, V, Dragani, A, Elli, E, Finazzi, G, Iurlo, A, Lanzarone, G, Lissandrini, L, Palandri, F, Paoli, C, Rambaldi, A, Ranalli, Paola, Randi, Ml, Ricco, A, Rossi, Elena, Ruggeri, M, Specchia, G, Timillero, A, Turnu, L, Vianelli, N, Vannucchi, Am, Rodeghiero, F, Patrono, Carlo, De Stefano V (ORCID:0000-0002-5178-5827), Rocca B (ORCID:0000-0001-8304-6423), Soldati D, Petrucci G (ORCID:0000-0002-9280-3673), Betti S, Ranalli P, Rossi E (ORCID:0000-0002-7572-9379), Patrono C, De Stefano, Valerio, Rocca, Bianca, Tosetto, A, Soldati, Denise, Petrucci, Giovanna, Beggiato, E, Bertozzi, I, Betti, Silvia, Carli, G, Carpenedo, M, Cattaneo, D, Cavalca, V, Dragani, A, Elli, E, Finazzi, G, Iurlo, A, Lanzarone, G, Lissandrini, L, Palandri, F, Paoli, C, Rambaldi, A, Ranalli, Paola, Randi, Ml, Ricco, A, Rossi, Elena, Ruggeri, M, Specchia, G, Timillero, A, Turnu, L, Vianelli, N, Vannucchi, Am, Rodeghiero, F, Patrono, Carlo, De Stefano V (ORCID:0000-0002-5178-5827), Rocca B (ORCID:0000-0001-8304-6423), Soldati D, Petrucci G (ORCID:0000-0002-9280-3673), Betti S, Ranalli P, Rossi E (ORCID:0000-0002-7572-9379), and Patrono C

Abstract

Once-daily (od), low-dose aspirin (75–100 mg) is recommended to reduce the thrombotic risk of patients with essential thrombocytemia (ET). This practice is based on data extrapolated from other high-risk patients and an aspirin trial in polycythemia vera, with the assumption of similar aspirin pharmacodynamics in the two settings. However, the pharmacodynamics of low-dose aspirin is impaired in ET, reflecting accelerated renewal of platelet cyclooxygenase (COX)-1. ARES is a parallel-arm, placebo-controlled, randomized, dose-finding, phase II trial enrolling 300 ET patients to address two main questions. First, whether twice or three times 100 mg aspirin daily dosing is superior to the standard od regimen in inhibiting platelet thromboxane (TX)A2 production, without inhibiting vascular prostacyclin biosynthesis. Second, whether long-term persistence of superior biochemical efficacy can be safely maintained with multiple vs. single dosing aspirin regimen. Considering that the primary study end point is serum TXB2, a surrogate biomarker of clinical efficacy, a preliminary exercise of reproducibility and validation of this biomarker across all the 11 participating centers was implemented. The results of this preliminary phase demonstrate the importance of controlling reproducibility of biomarkers in multicenter trials and the feasibility of using serum TXB2 as a reliable end point for dose-finding studies of novel aspirin regimens.

Published
2018

44. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Author

Barbui, T, De Stefano, V, Carobbio, A, Di Lazzaro, V, Guglielmelli, P, Iurlo, A, Finazzi, M, Rumi, E, Cervantes, F, Elli, E, Randi, Ml, Griesshammer, M, Palandri, F, Bonifacio, M, Hernandez, E, Cacciola, Rossella Rosaria, Cacciola, E, Palova, M, Carli, G, Beggiato, E, Martinelli, E, Musolino, C, Gaidano, G, Tieghi, A, Lunghi, F, Loscocco, G, Cattaneo, D, Cortelezzi, A, Betti, S, Rossi, E, Finazzi, G, Censori, B, Cazzola, M, Bellini, M, Arellano, V, Bertozzi, I, Sadiadian, P, Vianelli, N, and Scaffidi, L.

Published
2017

46. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

47. Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients

Author

Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2017

48. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level o 11 g/dl, to circulating blasts 3%, and to CALR-unmutated genotype, 1 point to platelet count o 150 × 109/l and to constitutional symptoms, and 0.15 points to any year of age. Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) allocated SMF patients into four risk categories with different survival (P o 0.0001): low (median survival NR; 133 patients), intermediate-1 (9.3 years, 95% CI: 8.1-NR; 245 patients), intermediate-2 (4.4 years, 95% CI: 3.2–7.9; 126 patients), and high risk (2 years, 95% CI: 1.7–3.9; 75 patients). Finally, we found that the MYSEC-PM represents the most appropriate tool for SMF decision-making to be used in clinical and trial settings.

Published
2017

49. Gran Torino: graduation studio TU Eindhoven and Politecnico di Torino, 2014-2015

Author

Apelt, H., Perona, G., Malcovati, S., Rapp, C., Bordian, A., Bosman, K.M.J., Delia, A., Gelzinyte, D., van Kaathoven, B.A.H.L., van der Linde, J., Lulja, K., Matta, A., Palandri, F., Penna, L., Rigas, E., Roeleveld, J., Santanera, N., Simons, J.P.G., Wehr, D.M., Zedda, I.M., Rational Architecture, and Built Environment

Abstract

This publication results from a year-lasting (2014-2015) collaboration between the Polytechnic University of Turin and Eindhoven Technical University’s Chair of Rational Architecture, guided by Professor Christian Rapp together with Haike Apelt as Dutch Supervisors and Professor Silvia Malcovati as Italian Supervisor.

Published
2016

50. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

Author

Andriani, A., Latagliata, R., Anaclerico, B., Spadea, A., Rago, A., Di Veroli, A., Spirito, F., Porrini, R., De Muro, M., Crescenzi Leonetti, S., Villiva, N., De Gregoris, C., Montefusco, E., Polverelli, N., Santoro, C., Breccia, M., Cimino, G., Majolino, I., Mazzucconi, M. G., Vianelli, N., Alimena, G., Montanaro, M., and Palandri, F.

Subjects
Adult, Male, Databases, Factual, Platelet Count, Thrombosis, Janus Kinase 2, Middle Aged, Prognosis, Risk Factors, Mutation, Splenomegaly, Humans, Female, Platelet Aggregation Inhibitors, Aged, Retrospective Studies, Thrombocythemia, Essential, Ultrasonography
Abstract

Spleen enlargement, present in 10-20% of Essential Thrombocythemia (ET) patients at diagnosis, is a feature clinically easy to assess, confirmable by echography with a very low chance of misinterpretation. Nonetheless, the clinical and prognostic role of splenomegaly has been seldom evaluated. From 1979 to 2013, 1297 ET patients retrospectively collected in the database of the Lazio Cooperative Group and Bologna University Hospital were evaluable for spleen enlargement at diagnosis and included in the analysis. On the whole, spleen was enlarged in 172/1297 (13.0%) patients; in most cases (94.8%) splenomegaly was mild (≤5 cm). Patients with splenomegaly were younger, predominantly male, presented higher platelet count and JAK2V617F allele burden and had a lower incidence of concomitant cardiovascular risk factors. At least one thrombotic event during follow-up occurred in 97/1,125 (8.6%) patients without spleen enlargement compared to 27/172 (15.7%) patients with spleen enlargement (P = 0.003). Despite comparable use of cytoreductive/antiplatelet therapies in the two groups, the cumulative risk of thrombosis at 5 years was significantly higher in patients with baseline splenomegaly (9.8% versus 4.4% in patients without splenomegaly, P = 0.012). In multivariate analysis exploring risk factors for thrombosis, splenomegaly retained its negative prognostic role, together with previous thrombosis, leucocyte count and male gender. Baseline splenomegaly seems to be an independent additional risk factor for thrombosis in nonstrictly WHO-defined ET patients. This data could be useful in the real-life clinical management of these patients.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results